Articles On Alcidion Group (ASX:ALC)
Title | Source | Codes | Date |
---|---|---|---|
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns
The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX Paradigm Biopharmaceuticals rose 151% in Novembe... |
Stockhead | ALC | 3 weeks ago |
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech
Healthcare technology company Alcidion Group Ltd (ASX:ALC) has signed a contract with Peninsula Health allowing the latter to use its Miya Precision platform which facilitates various aspects of patient data management. The contract – wh... |
themarketonline.com.au | ALC | 1 month ago |
Australian Broker Call *Extra* Edition – Nov 19, 2024
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha... |
FNArena | ALC | 1 month ago |
Alcidion signs $4.5m contract with NALHN for Miya Precision and Smartpage solutions
Health software developer Alcidion Group (ASX: ALC) has signed a $4.5 million contract with Northern Adelaide Local Health Network (NALHN) for the use of its Miya Precision smart platform and Smartpage mobile clinical task management soluti... |
SmallCaps | ALC | 1 month ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | ALC | 1 month ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | ALC | 2 months ago |
The Overnight Report: The Nervous Wait
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7963.00 + 11.00 0.14% S&P ASX 200 7982.40 +... |
FNArena | ALC | 3 months ago |
The Overnight Report: Not Comfortable, Sam
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7940.00 + 2.00 0.03% S&P ASX 200 7950.50 – 1... |
FNArena | ALC | 3 months ago |
The Overnight Report: September Has Arrived!
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7971.00 – 99.00 – 1.23% S&P ASX 200 8103.20... |
FNArena | ALC | 3 months ago |
FNArena Corporate Results Monitor – 03-09-2024
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALC)) - Alcid... |
FNArena | ALC | 3 months ago |
Digital prescription: ASX stocks transforming healthcare sector
A cooperative research centre believes there is an opportunity to transform Australia’s healthcare sector through digital innovations Alcidion helps health organisations harnesses the power of technology to empower digitally enabled care B... |
Stockhead | ALC | 4 months ago |
The Overnight Report: Jackson Hole
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7948.00 – 43.00 – 0.54% S&P ASX 200 8027.00... |
FNArena | ALC | 4 months ago |
Dr Boreham’s Crucible: Can this Aussie medtech rise as it lifts a cumbersome NHS into the digital age?
The resounding message across the seas that Great Britain used to rule is that the state of the Old Blighty is not at all healthy, with the country just exiting recession. But what resiliently remains healthy is the ‘growth’ prospects for t... |
Stockhead | ALC | 4 months ago |
ALC ASX | Alcidion Group Ltd | Market Insights, News
|
Livewire | ALC | 4 months ago |
Australian Broker Call *Extra* Edition – Aug 06, 2024
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin An additional news report on the recommendation, valuation, forecast and opinion cha... |
FNArena | ALC | 4 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | ALC | 4 months ago |
ASX July Winners: The best 50 stocks in a strong month for markets
S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders... |
Stockhead | ALC | 4 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | ALC | 4 months ago |
2 ASX healthcare shares outperforming on big news
ASX healthcare shares are in the red on Tuesday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) down 0.46% and the S&P/ASX 200 Index (ASX: XJO) down 0.96% in early trading. As always, there are outliers, and these two ASX hea... |
Motley Fool | ALC | 5 months ago |
Closing Bell: ASX axed in regional rout while mini-biotech Tissue Repair soars on TGA nod
ASX and regional markets are sharply lower after Wall St tech crunch All 11 local sectors hit, InfoTech smashed hardest on -2.7pc Tissue Repair leads small caps on happy TGA approval news The benchmark has followed sharp falls across... |
Stockhead | ALC | 5 months ago |
Alcidion chosen as preferred supplier for North Cumbria’s new AI-Driven patient record system
Alcidion Group (ASX: ALC) has been selected as the preferred supplier for a new electronic patient record (EPR) system being implemented by North Cumbria Integrated Care NHS Foundation Trust (NCIC) in the UK. The system will provide clinici... |
SmallCaps | ALC | 5 months ago |
ASX Health Stocks: Immutep gets crucial therapy trial clearance; Alcidion wins $4m deal
Immutep has received regulatory clearance from the Netherlands for its Phase I clinical trial of IMP761 Alcidion nabs $4m contract in a long-term partnership with Hume Rural Health Alliance Immutep has clearance for Phase 1 trial Immute... |
Stockhead | ALC | 5 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | ALC | 5 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | ALC | 6 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | ALC | 7 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | ALC | 8 months ago |
Australian Broker Call *Extra* Edition – Mar 12, 2024
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | ALC | 9 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | ALC | 9 months ago |
Market Highlights: Records tumble, Powell to testify, and 5 ASX small caps to watch today
ASX to edge lower after Wall Street pulls back Gold and Bitcoin both touched all time highs Jerome Powell’s testimony later today US time The ASX is poised to edge lower on Wednesday, tracking movements on Wall Street. At 8am AEDT,... |
Stockhead | ALC | 9 months ago |
FNArena Corporate Results Monitor – 05-03-2024
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((ALC)) – Alcidion Group ((LVH)) – LiveHire Check it out at https://www.fnarena.com/index.php/reporting_season/ Welcome to the FNArena Corporate Results Monitor: Subscrib... |
FNArena | ALC | 9 months ago |
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales
Healius has new CEO Nove Eye reports record US sales in February Cynata says first patient has been enrolled in Phase 2 trial Healius has a new CEO, shares rip higher Healius (ASX:HLS) jumped 14% this morning after announcing that it wo... |
Stockhead | ALC | 9 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | ALC | 10 months ago |
Australian Broker Call *Extra* Edition – Feb 09, 2024
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | ALC | 10 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | ALC | 1 year ago |
Australian Broker Call *Extra* Edition – Nov 09, 2023
An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now... |
FNArena | ALC | 1 year ago |
The Overnight Report: Another Day…
World Overnight SPI Overnight 6989.00 – 1.00 – 0.01% S&P ASX 200 6977.10 – 20.30 – 0.29% S&P500 4378.38 + 12.40 0.28% Nasdaq Comp 13639.86 + 121.08 0.90% DJIA 34152.60 + 56.74 0.17% S&P500 VIX 14.81 – 0.08 – 0.54%... |
FNArena | ALC | 1 year ago |
The Overnight Report: And Breathe
World Overnight SPI Overnight 6993.00 – 11.00 – 0.16% S&P ASX 200 6997.40 + 19.20 0.28% S&P500 4365.98 + 7.64 0.18% Nasdaq Comp 13518.78 + 40.50 0.30% DJIA 34095.86 + 34.54 0.10% S&P500 VIX 15.02 + 0.11 0.74% US... |
FNArena | ALC | 1 year ago |
The Fed helps support equities: Origin (ASX:ORG) bid in doubt despite improved price
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.90% to 6899.70. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify.... |
Rask Media | ALC | 1 year ago |
Closing Bell: Ahead of big date with US cash rate, ASX puts October to bed with brash November debut
ASX200 climbs a very laudable +0.85% Property stocks (+1.9%) and Health Care (+1.24%) have led the gains Small caps led by Loyalty Lithium, TG6 and Tambourah Metals The Australian sharemarket has lifted strongly on the first day of the... |
Stockhead | ALC | 1 year ago |
Why is the Alcidion share price crashing 27% to a 52-week low?
The Alcidion Group Ltd (ASX: ALC) share price has returned from its trading halt and sunk deep into the red. At the time of writing, the healthcare technology company's shares are down 27% to a 52-week low of 7.1 cents. What's going on wit... |
Motley Fool | ALC | 1 year ago |
Atlas Arteria: Updating for the new French tax impost
Atlas Arteria's (ASX:ALC) recent share price decline reflects the material downgrade to distributions receivable by ALX from its key French toll road assets as a result of the proposed new French tax. |
Morgans | ALC | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | ALC | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | ALC | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | ALC | 1 year ago |
FNArena Corporate Results Monitor – 25-08-2023
Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((AX1)) - Accent Group ((A1M)) - AIC Mines ((AIZ)) - Air New Zealand ((ALC)) - Alcidion Group ((ALK)) - Alkane Resources ((APA)) - APA Group ((A1N)) - ARN Media ((AIA)) -... |
FNArena | ALC | 1 year ago |
400% organic growth in 3 years: The ASX small-cap Cyan is pumped about
Those investors with small-cap ASX shares in their portfolio have suffered greatly over the past couple of years. Since inflation rocketed, interest rates followed, and Russia stamped into Ukraine, money was pulled out from smaller player... |
Motley Fool | ALC | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | ALC | 1 year ago |
An unloved ASX stock I’m considering buying with $5,000 in August
Frustration can’t begin to describe what it’s like to own certain ASX stocks. The business is excellent — winning new customers, expanding market share — but the stock price just languishes, or even plunges. Even with a long-term horizon,... |
Motley Fool | ALC | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | ALC | 1 year ago |
ASX July Winners: Easing inflation, AI, and an oil rally lure sidelined traders back to risky assets
The ASX was higher by around 2.5% in July The best sectors were Tech and Energy We look at the best and worst performing ASX stocks for the month For the month of July, most major indexes on the ASX rose by around 2.5%. Name % Change... |
Stockhead | ALC | 1 year ago |